Back to Main

Trevena postpones IPO

By: Renaissance Capital
Posted: 11/20/2013 7:02:00 AM
Referenced Stocks: TRVN

Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, postponed its IPO on Wednesday citing poor market conditions. The King of Prussia, PA-based company was founded in 2007. Barclays and Jefferies & Co. were set to be the joint bookrunners on the deal.